Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

Micro-Abstract The oncogenic driver epidermal growth factor receptor (EGFR) mutations upregulate immune checkpoint proteins programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) in in vitro and in vivo models of non–small-cell lung cancer (NSCLC). Immunohistochemistry revealed that PD-L1 and P...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2015-09, Vol.16 (5), p.e25-e35
Hauptverfasser:	Lin, Cheng, Chen, Xiong, Li, Meifang, Liu, Jingnan, Qi, Xingfeng, Yang, Wenting, Zhang, Hairong, Cai, Zhongfu, Dai, Yun, Ouyang, Xuenong
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma of Lung Adult Aged Aged, 80 and over Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use B7-H1 Antigen - genetics Biomarkers, Tumor - metabolism Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Disease-Free Survival EGFR mutation EGFR-TKI therapy ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Female Follow-Up Studies Gene Expression Regulation, Neoplastic Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Lung adenocarcinoma Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Male Middle Aged Mutation PD-L1 Prognosis Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!